OliX PharmaceuticalsInc (226950) - Total Assets
Based on the latest financial reports, OliX PharmaceuticalsInc (226950) holds total assets worth ₩195.37 Billion KRW (≈ $132.40 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can OliX PharmaceuticalsInc service its debt to assess how comfortably operating cash covers total debt obligations.
OliX PharmaceuticalsInc - Total Assets Trend (2016–2025)
This chart illustrates how OliX PharmaceuticalsInc's total assets have evolved over time, based on quarterly financial data. See 226950 book value for net asset value and shareholders' equity analysis.
OliX PharmaceuticalsInc - Asset Composition Analysis
Current Asset Composition (December 2025)
OliX PharmaceuticalsInc's total assets of ₩195.37 Billion consist of 72.1% current assets and 27.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 3.3% |
| Accounts Receivable | ₩5.13 Billion | 2.6% |
| Inventory | ₩396.71 Million | 0.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.94 Billion | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how OliX PharmaceuticalsInc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of OliX PharmaceuticalsInc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OliX PharmaceuticalsInc's current assets represent 72.1% of total assets in 2025, an increase from 66.6% in 2016.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2025, down from 4.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 2.6% of total assets.
OliX PharmaceuticalsInc Competitors by Total Assets
Key competitors of OliX PharmaceuticalsInc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
OliX PharmaceuticalsInc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.60 | 0.52 | 13.30 |
| Quick Ratio | 6.59 | 0.50 | 13.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩119.53 Billion | ₩-14.53 Billion | ₩60.10 Billion |
OliX PharmaceuticalsInc - Advanced Valuation Insights
This section examines the relationship between OliX PharmaceuticalsInc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.61 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 174.2% |
| Total Assets | ₩195.37 Billion |
| Market Capitalization | $1.29 Billion USD |
Valuation Analysis
Below Book Valuation: The market values OliX PharmaceuticalsInc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: OliX PharmaceuticalsInc's assets grew by 174.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for OliX PharmaceuticalsInc (2016–2025)
The table below shows the annual total assets of OliX PharmaceuticalsInc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩195.37 Billion ≈ $132.40 Million |
+174.20% |
| 2024-12-31 | ₩71.25 Billion ≈ $48.28 Million |
-30.71% |
| 2023-12-31 | ₩102.83 Billion ≈ $69.68 Million |
-22.48% |
| 2022-12-31 | ₩132.65 Billion ≈ $89.90 Million |
+53.05% |
| 2021-12-31 | ₩86.67 Billion ≈ $58.74 Million |
+10.30% |
| 2020-12-31 | ₩78.58 Billion ≈ $53.25 Million |
+73.82% |
| 2019-12-31 | ₩45.21 Billion ≈ $30.64 Million |
-18.75% |
| 2018-12-31 | ₩55.64 Billion ≈ $37.70 Million |
+157.10% |
| 2017-12-31 | ₩21.64 Billion ≈ $14.67 Million |
+42.85% |
| 2016-12-31 | ₩15.15 Billion ≈ $10.27 Million |
-- |
About OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more